Semaglutide vs Tirzepatide: What the Clinical Trials Actually Show

The Head-to-Head Trial: SURMOUNT-5

SURMOUNT-5 enrolled 751 adults with obesity (BMI 30 or higher) and no type 2 diabetes. Participants were randomized to receive either tirzepatide or semaglutide at their maximum tolerated doses for 72 weeks. The trial was open-label, meaning both patients and doctors knew which medication they were taking.

The difference was 6.5 percentage points. To put that in context: for someone weighing 220 lbs, that translates to roughly 14 additional pounds lost with tirzepatide over the same period.

One important detail: fewer participants dropped out due to GI side effects on tirzepatide (2.7%) compared to semaglutide (5.6%). This matters because nausea and vomiting are the most common reasons people stop GLP-1 medications.

A follow-up analysis published in the European Heart Journal Open found tirzepatide also showed greater 10-year cardiovascular disease risk reduction in the same patient group.

How They Work: One Target vs Two

The fundamental difference between these medications is what they target in your body.

Semaglutide (Wegovy®, Ozempic®)

Semaglutide is a GLP-1 receptor agonist. It mimics a single hormone called GLP-1 (glucagon-like peptide-1) that your gut naturally produces after eating. GLP-1 slows how fast your stomach empties, tells your brain you are full, and helps regulate blood sugar. The medication amplifies this signal so it lasts longer and is stronger than what your body produces on its own.

Tirzepatide (Zepbound®, Mounjaro®)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, the first in its class. It targets two hormones instead of one: GLP-1 (the same one semaglutide targets) and GIP (glucose-dependent insulinotropic polypeptide). Research published in JCI Insight shows this dual mechanism improves insulin sensitivity and beta-cell function beyond what GLP-1 alone achieves.

Interestingly, tirzepatide actually binds to the GLP-1 receptor with about 5 times weaker affinity than native GLP-1. Its stronger effects appear to come from the combined action of both pathways working together, rather than from hitting GLP-1 harder.

Weight Loss Results from Clinical Trials

Beyond the head-to-head trial, both medications have been studied extensively in their own trial programs. These numbers come from the largest trials in each program.

Semaglutide: The STEP Trials

The STEP program enrolled nearly 5,000 participants across multiple trials. In STEP 1 (1,961 participants, 68 weeks), semaglutide 2.4 mg produced an average weight loss of 14.9% compared to 2.4% on placebo. Half of participants lost 15% or more of their body weight.

The longest data comes from STEP 5, which followed participants for 2 full years. At 104 weeks, average weight loss was 15.2%, and 77% of participants lost at least 5% of their body weight. Weight loss was sustained over the full study period without regain while on medication.

Tirzepatide: The SURMOUNT Trials

SURMOUNT-1 was the largest trial, enrolling 2,539 participants over 72 weeks. At the highest dose (15 mg), average weight loss was 20.9%. Nearly 40% of participants lost 25% or more of their body weight, which is close to what bariatric surgery typically achieves.

Keep in mind these are averages. Individual results vary widely based on starting weight, adherence to the medication, dietary changes, exercise, and other factors. Some participants in both programs lost significantly more than the average. Others lost less.

What About Weight Regain?

A January 2026 Oxford/BMJ meta-analysis of 37 studies found that people who stop GLP-1 medications regain weight at about 0.8 kg (1.8 lbs) per month. At that rate, most people return to their pre-treatment weight within about 18 months.

SURMOUNT-4 showed this directly: participants who switched from tirzepatide to placebo regained 14% of their body weight over 52 weeks, while those who continued lost an additional 5.5%. A follow-up analysis found that 82.5% of those who stopped regained at least 25% of the weight they had lost.

This is one of the most important findings for anyone considering these medications: current evidence suggests they work best as long-term treatment, similar to medications for blood pressure or cholesterol. Stopping typically means regaining.

Side Effects: What the Trials Found

GI side effects are the most common issue with both medications. Most occur during dose escalation (the first few months while your body adjusts) and tend to decrease over time. The key difference: semaglutide at its weight-loss dose appears to cause more nausea and vomiting than tirzepatide at its weight-loss dose.

Side effect data for semaglutide comes from the Wegovy FDA prescribing information and STEP 1-3 pooled analysis. Tirzepatide data comes from SURMOUNT-1 GI tolerability analysis and the Zepbound FDA prescribing information.

Managing Side Effects

Clinical guidelines recommend a "start low, go slow" approach. Both medications begin at lower doses and increase gradually. If nausea persists at a particular dose, providers can extend the time at that dose before increasing. Eating smaller meals, avoiding greasy or spicy foods, and staying hydrated also help. Some providers prescribe anti-nausea medication during the adjustment period.

Beyond GI: Other Safety Considerations

Both medications carry a boxed warning about thyroid C-cell tumors based on findings in rodent studies. A systematic review of 10 clinical trials involving over 14,500 human participants found less than 1% developed any thyroid cancer, with no evidence of a causal link. The European Medicines Agency reviewed the same data and found "no evidence to suggest a causal relationship." However, both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC).

Gallbladder issues are more clearly associated with GLP-1 medications. A JAMA Internal Medicine meta-analysis found a 37% higher relative risk of gallbladder disease. Rapid weight loss itself increases gallstone risk regardless of the method, so this may be partially related to the amount of weight lost rather than the medication directly.

The Suicide Question: Resolved

On January 13, 2026, the FDA requested manufacturers remove the suicidal ideation warning from GLP-1 medication labels. Their review analyzed 91 placebo-controlled trials involving nearly 108,000 patients and found no increased risk of suicidal thoughts or behavior. A separate analysis using the FDA Sentinel System (over 2.2 million patients) confirmed the finding. If this concern delayed your decision, the evidence is now clear.

What They Actually Cost

List prices for both medications are over $1,000 per month. But very few people pay list price. Manufacturer savings programs, insurance coverage, and compounded alternatives all change the math significantly.

*Compounded medications are NOT FDA-approved. Compounded semaglutide and tirzepatide face increasing regulatory scrutiny as the FDA declared drug shortages resolved. Availability varies. See our provider comparison for current options.

Compounded medications are pharmacy-prepared and have not gone through the clinical trials referenced on this page. Our compounded GLP-1 safety guide covers what to look for if you're considering that route.

If you have commercial insurance that covers either medication, the out-of-pocket cost is similar. The bigger difference shows up for people paying cash: semaglutide's NovoCare program is $199-$349/month, while Zepbound through LillyDirect runs $299-$449/month. The oral Wegovy pill (approved December 2025) adds another option at $149-$299/month through NovoCare.

Annual cost at maintenance doses without insurance: roughly $4,200 for brand-name semaglutide injection, $5,400 for brand-name tirzepatide injection. These are manufacturer self-pay programs, not list prices.

What Each Medication Is FDA-Approved For

This is where semaglutide has a significant advantage. It has been on the market longer and has more approved uses.

The cardiovascular risk reduction approval for semaglutide is based on the SELECT trial, which enrolled 17,604 patients and found a 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death). This is the largest GLP-1 outcomes trial completed to date.

Tirzepatide has its own unique approval: it is the first medication ever approved by the FDA for obstructive sleep apnea in adults with obesity. The SURMOUNT-OSA trial showed up to a 58.7% reduction in the apnea-hypopnea index.

For someone whose primary concern is weight loss, both are FDA-approved for that purpose. But if you also have cardiovascular risk, kidney disease, or liver disease, semaglutide has the broader evidence base. If sleep apnea is a concern, tirzepatide has the specific approval.

Which Medication Fits Your Situation

Your doctor will make the final prescribing decision based on your health history, other medications, insurance coverage, and individual needs. But this framework can help you think about the question before that conversation.

Insurance coverage often narrows the choice. Your plan might cover one medication but not the other, or require trying semaglutide first (step therapy) before approving tirzepatide. If cost is the primary constraint and you are paying out of pocket, semaglutide currently has more affordable access points through NovoCare and the new oral pill.

Neither medication is a standalone solution. Clinical trials that produced these results included dietary counseling and activity recommendations. The medication reduces appetite and helps with adherence, but the lifestyle component matters for long-term outcomes.

The Bottom Line

Tirzepatide produces more weight loss and appears to be better tolerated based on the SURMOUNT-5 head-to-head data. On the other hand, semaglutide has been on the market longer, carries more FDA-approved indications including cardiovascular risk reduction, offers an oral pill option, and costs less through manufacturer cash-pay programs.

Both are prescription medications that require evaluation by a licensed clinician. Your health history, existing conditions, insurance coverage, and personal preferences all factor into which one makes sense for you.

The most important step is the conversation with a provider who can evaluate your specific situation. The data in this guide gives you the foundation for that conversation.

How We Evaluate Weight Loss Programs

When comparing telehealth providers for weight management, we look at medical oversight quality, medication options (brand-name, compounded, or both), support structure, pricing transparency, and insurance compatibility. Our goal is to help you understand what each provider offers so you can make an informed decision.

Featured Programs with Clinician Support

These programs include licensed clinician consultations and structured support. Compare what's included before deciding.

Sources

1. Aronne LJ, Sattar N, Horn DB, et al. Tirzepatide vs semaglutide for weight reduction (SURMOUNT-5). N Engl J Med. 2025.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
4. Garvey WT, Frias JP, Jastreboff AM, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091.
5. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT). N Engl J Med. 2023;389(24):2221-2232.
7. Thomas CE, et al. Mechanism of action differences between semaglutide and tirzepatide. JCI Insight. 2020.
8. FDA Drug Safety Communication. Update on evaluation of suicidal thoughts with GLP-1 RAs. January 13, 2026.
9. University of Oxford/BMJ. Stopping weight loss drugs linked to weight regain. January 2026.
10. He L, et al. GLP-1 RAs and gallbladder disease: systematic review. JAMA Intern Med. 2022.
11. Alkhezi OS, et al. Thyroid cancer risk with semaglutide: systematic review. 2024.